Eiger BioPharmaceuticals Inc (EIGR.OQ)
EIGR.OQ on NASDAQ Stock Exchange Global Market
11.85USD
24 Sep 2018
11.85USD
24 Sep 2018
Change (% chg)
-- (--)
-- (--)
Prev Close
$11.85
$11.85
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
37,033
37,033
52-wk High
$18.00
$18.00
52-wk Low
$7.50
$7.50
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Jun '18 | 0.00 | -0.823 |
| Mar '18 | 0.00 | -0.839 | |
| FY 2017 | Dec '17 | 0.00 | -1.110 |
| Sep '17 | 0.00 | -1.095 | |
| Jun '17 | 0.00 | -1.332 | |
| Mar '17 | 0.00 | -1.344 | |
| FY 2016 | Dec '16 | 0.00 | -1.525 |
| Sep '16 | 0.00 | -1.492 | |
| Jun '16 | 0.00 | -1.867 | |
| Mar '16 | 0.00 | -10.418 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-18 | 5 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Dec-18 | 5 | 0.00 | 0.00 | 0.00 | 0.00 |
| Year Ending Dec-18 | 6 | 0.00 | 0.00 | 0.00 | 3.33 |
| Year Ending Dec-19 | 7 | 8.92 | 50.00 | 0.00 | 9.78 |
| Earnings (per share) | |||||
| Quarter Ending Sep-18 | 6 | -0.74 | -0.60 | -0.83 | -1.37 |
| Quarter Ending Dec-18 | 6 | -0.70 | -0.53 | -0.86 | -1.41 |
| Year Ending Dec-18 | 6 | -3.01 | -2.71 | -3.35 | -4.94 |
| Year Ending Dec-19 | 7 | -2.67 | 0.35 | -3.82 | -4.65 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 85.68 | 32.76 | |
| P/E High - Last 5 Yrs. | -- | 300.70 | 45.44 | |
| P/E Low - Last 5 Yrs. | -- | 92.08 | 24.26 | |
| Beta | 2.57 | 0.93 | 0.89 | |
| Price to Sales (TTM) | -- | 114.98 | 5.74 | |
| Price to Book (MRQ) | 5.20 | 15.51 | 5.00 | |
| Price to Tangible Book (MRQ) | 5.20 | 14.62 | 6.57 | |
| Price to Cash Flow (TTM) | -- | 72.88 | 23.29 | |
| % Owned Institutions | 68.95 | 14.70 | 2.21 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 0.36 | 1.51 | |
| Dividend Yield - 5 Year Avg | -- | 0.26 | 1.52 | |
| Dividend 5 Year Growth Rate | -- | 1.72 | 5.22 | |
| Payout Ratio(TTM) | -- | 16.50 | 43.78 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -- | 411.54 | 8.01 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -- | 80.36 | 5.64 | |
| Sales - 5 Yr. Growth Rate | -- | 32.26 | 10.18 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | 28.66 | 29.14 | 20.61 | |
| EPS (TTM) vs TTM 1 Yr. Ago | 89.21 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 39.84 | 10.66 | |
| Capital Spending - 5 Yr. Growth Rate | -- | 40.42 | 15.34 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 1.91 | 2.22 |
| Current Ratio (MRQ) | 7.01 | 5.46 | 3.03 |
| LT Debt to Equity (MRQ) | 72.07 | 35.27 | 12.51 |
| Total Debt to Equity (MRQ) | 72.07 | 37.09 | 16.85 |
| Interest Coverage (TTM) | -30.39 | -102.34 | 32.72 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 39.18 | 54.37 | |
| Gross Margin - 5 Yr. Avg. | -- | 50.58 | 52.16 | |
| EBITD Margin (TTM) | -- | -- | -- | |
| EBITD - 5 Yr. Avg | -- | -600.62 | 10.68 | |
| Operating Margin (TTM) | -- | -759.68 | 4.33 | |
| Operating Margin - 5 Yr. Avg. | -- | -621.65 | 6.11 | |
| Pre-Tax Margin (TTM) | -- | -733.53 | 5.18 | |
| Pre-Tax Margin - 5 Yr. Avg. | -- | -627.35 | 6.51 | |
| Net Profit Margin (TTM) | -- | -734.90 | 1.48 | |
| Net Profit Margin - 5 Yr. Avg. | -- | -630.40 | 2.78 | |
| Effective Tax Rate (TTM) | -- | 23.33 | 23.11 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 18.66 | 23.97 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 0 | 23,229,030 | 860,305,026 | |
| Net Income/Employee (TTM) | -2,326,150 | 3,144,146 | 101,198,978 | |
| Receivable Turnover (TTM) | -- | 20.89 | 5.87 | |
| Inventory Turnover (TTM) | -- | 2.46 | 3.41 | |
| Asset Turnover (TTM) | 0.00 | 0.41 | 0.94 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -105.46 | -0.15 | 11.13 | |
| Return on Assets - 5 Yr. Avg. | -53.65 | 3.51 | 12.40 | |
| Return on Investment (TTM) | -116.96 | 1.79 | 14.61 | |
| Return on Investment - 5 Yr. Avg. | -67.98 | 2.56 | 16.13 | |
| Return on Equity (TTM) | -143.95 | 3.28 | 16.33 | |
| Return on Equity - 5 Yr. Avg. | -- | 3.43 | 17.39 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -- | -- | -- |
| EPS (TTM) % | 87.39 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Eiger BioPharmaceuticals Inc
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
Institutional Holders
| % Shares Owned: | 75.34% |
| # of Holders: | 78 |
| Total Shares Held: | 10,732,135 |
| 3 Mo. Net Change: | 2,914,262 |
| # New Positions: | 19 |
| # Closed Positions: | 7 |
| # Increased Positions: | 37 |
| # Reduced Positions: | 19 |
| # Net Buyers: | 18 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.